www.aasraw.com
How To Treat Your Lung Cancer?
There are many ways to treat lung cancer. Surgery and radiation are used to treat only the cancer. They do not affect the rest of the body. Chemo drugs, targeted therapy, and immunotherapy go through the whole body. They can reach cancer cells almost anywhere in the body. The treatment for lung cancer can include surgery, radiation, chemotherapy, targeted therapy, and immunotherapy. The treatment plan that’s best for you will depend on: The stage of the cancer The chance that a type of treatment will help Your age Other health problems you have Your feelings about the treatment and the side effects that may come with it.
Many patients with lung cancer choose drug therapy in the early stage, because it is the most direct and simple way to control the spread of cancer cells. The following drugs are commonly used to treat lung cancer(SCLC and NSCLC): 1
AASraw Biochemical Technology Co.,Ltd aas14@aasraw.com
www.aasraw.com
❶ AZD-3759(CAS:1626387-80-1) AZD-3759 is a potent epidermal growth factor receptor(EGFR) inhibitor, with potential antineoplastic activity. AZD-3759 binds to and inhibits the activity of EGFR as well as certain mutant forms of EGFR.This prevents EGFR-mediated signaling, and may lead to both induction of cell dealth and inhibition of tumor growth in EGFR-overexpressing cells.
❷ Gefitinib(CAS:184475-35-2) Gefitinib is a tyrosine kinase inhibitor used as first-line therapy to treat non-small cell lung carcinoma (NSCLC) that meets certain genetic mutation criteria. Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that binds to the adenosine triphosphate (ATP)-binding site of the enzyme. EGFR is often shown to be overexpressed in certain human carcinoma cells, such as lung and breast cancer cells. Overexpression leads to enhanced activation of the anti-apoptotic Ras signal transduction cascades, subsequently resulting in increased survival of cancer cells and uncontrolled cell proliferation. Gefitinib is the first selective inhibitor of the EGFR tyrosine kinase which is also referred to as Her1 or ErbB-1. By inhibiting EGFR tyrosine kinase, the downstream signaling cascades are also inhibited, resulting in inhibited malignant cell proliferation.
❸ AZD-9291(CAS:1421373-65-0) AZD-9291 is also called Osimertinib which is a tyrosine kinase inhibitor used in the treatment of certain types of non-small cell lung carcinoma. AZD-9291 is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that binds to certain mutant forms of EGFR (T790M, L858R, and exon 19 deletion) that predominate in non-small cell lung cancer (NSCLC) tumours following treatment with first-line 2
AASraw Biochemical Technology Co.,Ltd aas14@aasraw.com
www.aasraw.com
EGFR-TKIs. As a third-generation tyrosine kinase inhibitor, AZD-9291 is specific for the gate-keeper T790M mutation which increases ATP binding activity to EGFR and results in poor prognosis for late-stage disease. Furthermore, AZD-9291 has been shown to spare wild-type EGFR during therapy, thereby reducing non-specific binding and limiting toxicity.
❹ Dacomitinib(CAS:1110813-31-4) Dacomitinib is a medication used to treat non small cell lung cancer with EGFR exon 19 deletion of exon 21 L858R substitution. Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains. Dacomitinib is a medication for the treatment of non-small-cell lung carcinoma (NSCLC). It is a selective and irreversible inhibitor of EGFR.
❺ Ceritinib(CAS:1032900-25-6) Ceritinib is also called LDK378 that is an antineoplastic kinase inhibitor used to treat anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) in patients with inadequate clinical response or intolerance to crizotinib. Ceritinib is used for the treatment of adults with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) following failure (secondary to resistance or intolerance) of prior crizotinib therapy. About 4% of patients with NSCLC have a chromosomal rearrangement that generates a fusion gene between EML4 (echinoderm microtubule-associated protein-like 4) and ALK (anaplastic lymphoma kinase), which results in constitutive kinase activity that contributes to carcinogenesis and seems to drive the malignant phenotype. Ceritinib exerts its therapeutic effect by inhibiting autophosphorylation of ALK, ALK-mediated phosphorylation of the downstream signaling protein STAT3, and proliferation of 3
AASraw Biochemical Technology Co.,Ltd aas14@aasraw.com
www.aasraw.com
ALK-dependent cancer cells. Following treatment with crizotinib (a first-generation ALK inhibitor), most tumours develop drug resistance due to mutations in key “gatekeeper” residues of the enzyme. This occurrence led to development of novel second-generation ALK inhibitors such as ceritinib to overcome crizotinib resistance. The FDA approved ceritinib in April 2014 due to a surprisingly high response rate (56%) towards crizotinib-resistant tumours and has designated it with orphan drug status.
❻ Afatinib(CAS:439081-18-2) Afatinib is an antineoplastic agent used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with non-resistant EGFR mutations or resistance to platinum-based chemotherapy. Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim’s brand name Gilotrif. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test 4. Gilotrif (afatinib) is the first FDA-approved oncology product from Boehringer Ingelheim.
❼ Erlotinib(CAS:183321-74-6) Erlotinib is an EGFR tyrosine kinase inhibitor used to treat certain small cell lung cancers or advanced metastatic pancreatic cancers. It belongs to a class of drugs known as tyrosine kinase inhibitors. It works by blocking the function of a protein called the epidermal growth factor receptor (EGFR). The EGFR is found on the surface of many cancer cells as well as normal cells. It serves as an “antenna,” receiving signals from other cells and the environment that tell the cell to grow and divide. The EGFR plays an important role in growth and development prenatally and during childhood and helps to maintain normal replacement of old and damaged cells in adults. However, many cancer cells have unusually large amounts of the EGFR on their surface, or their EGFR has been altered by mutation of the DNA that 4
AASraw Biochemical Technology Co.,Ltd aas14@aasraw.com
www.aasraw.com
carries the genetic code for the protein. The result is that the signals coming from the EGFR are much too strong, leading to excessive cell growth and division, a hallmark of cancer. All of these drugs can be provided by aasraw in pure powder form, which is only for research purpose. Welcome to contact with aasraw if you want know more information about how to buy aganist lung cancer drugs!
5
AASraw Biochemical Technology Co.,Ltd aas14@aasraw.com